TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02853500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriNav
Description: TriNav is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Delivery
Description: Low profile tubing microcatheter for easier access to more peripheral/distal vascular branches for precise targeted delivery of medications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Medication used in cancer chemotherapy, including intraarterial delivery for liver malignancies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Medication used in cancer chemotherapy, including intraarterial delivery for liver malignancies.
Study: NCT00710229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: intravitreal injection
Study: NCT01048437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transplant education with video
Description: 1 hour standard transplant module is replaced with the Explore Transplant presentation and 20 minute video featuring transplant patients and donors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transplant education with speakers
Description: 1 hour standard transplant module is replaced with the Explore Transplant presentation and 3 live speakers: 1 deceased donor recipient, 1 living donor recipient and 1 living donor
Study: NCT04438005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: ICP-022 is a white, round, uncoated tablet, 50 mg. It is administered orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
Study: NCT03097120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.625 mg of conjugated equine estrogen
Description: one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate
Description: one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: two placebo tablets daily
Study: NCT01850420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-1
Study: NCT02769208

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Central air handling unit air purification technologies
Description: As described in the arm descriptions, the interventions involve changing the baseline pre-filter + HEPA + ESP conditions by removing either just the ESP or both the ESP and the HEPA for a five week period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Central air handling unit air purification technologies
Description: As described in the arm descriptions, the interventions involve changing the baseline pre-filter + HEPA + ESP conditions by removing either just the ESP or both the ESP and the HEPA for a five week period.
Study: NCT02199392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
Study: NCT03187002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate IV Sedation
Description: IV sedation with fentanyl and versed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SHAM: Transcutaneous electrical nerve stimulation (TENS)
Description: Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHAM: Moderate IV Sedation
Description: Sham IV to ensure blinding
Study: NCT00389636

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TheraGauze
Description: TheraGauze

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regranex
Description: Regranex + TheraGauze
Study: NCT02154308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL
Description: IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
Study: NCT02175264

Intervention type: GENETIC
Intervention: Blood sample
Study: NCT04913909

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Effects of an oral probiotic or placebo use on oral microbiota and glycemic index in Type 2 diabetic patients
Description: The participants were randomized to the interventional groups, probiotic or placebo, by the diabetes nurse. During the intervention period of 30 nights, the participants were asked to let one Dentoblis™ or placebo lozenge slowly melt in their mouth for one minute before going to bed and after tooth brushing. Dentoblis™, as a test lozenge, contains 4x109 CFU/g S. salivarius M18 strain isolated from a healthy oral microbiota and has been utilized as oral probiotic inhibiting dental caries-causing pathogens.~The placebo is indistinguishable in form, size, color, and taste from the probiotic lozenge, but contains no bacteria. Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code. Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Effects of an oral probiotic or placebo use on oral microbiota and glycemic index in Type 2 diabetic patients
Description: The participants were randomized to the interventional groups, probiotic or placebo, by the diabetes nurse. During the intervention period of 30 nights, the participants were asked to let one Dentoblis™ or placebo lozenge slowly melt in their mouth for one minute before going to bed and after tooth brushing. Dentoblis™, as a test lozenge, contains 4x109 CFU/g S. salivarius M18 strain isolated from a healthy oral microbiota and has been utilized as oral probiotic inhibiting dental caries-causing pathogens.~The placebo is indistinguishable in form, size, color, and taste from the probiotic lozenge, but contains no bacteria. Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code. Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse.
Study: NCT01238237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Superselective Intraarterial Cerebral Infusion of Cetuximab
Description: Intraarterial Mannitol 25% 3-10 ml to open the blood brain barrier followed by Intraarterial Cetuximab single dose (starting at 100mg/m2 and escalating up to 500mg/m2)
Study: NCT04752748

Intervention type: DRUG
Intervention: Drug protocol
Description: The following drug scheme was carried out: The patients began with methotrexate (MTX) 15 mg / week, which was increased to 25 mg / week until week 12. Subsequent steps for patients with an insufficient response (DAS28 score\> 3.2 and the Physician's Global Assessment (PGA)\> 4.0 \[0-10 cm\]) were leflunomide 20mg / day with MTX 15 mg / week from week 12 to week 24 and adalimumab twice a month and MTX 15mg / week from week 24 to week 48. The use of 5mg folic acid was advised once a week during the 48 weeks of the study. Three treatment failures were considered over these 48 weeks:~* Failure 1: failure of the first DMARD (MTX) in week 12.~* Failure 2: failure of the second DMARD (leflunomide) at week 24~* Failure 3: failure of the first immunobiological (adalimumab) at week 48.
Study: NCT00872079

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genomics
Description: Model predictive control is a computer based algorithm that can be applied to drug dosing. This computer tool uses a model of how a patient will respond to a drug dose based on demographic and historical dosing information to predict a new drug response. A drug dose controller applies all possible doses to the response model and selects the one dose that best meets the stated goals of the drug therapy. In the case of warfarin, we will calculate an international normalized ratio (INR) value within a specific target range.
Study: NCT00674999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion
Description: Application of Amnion with processing procedures involving the use of trypsin-EDTA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion
Description: Application of Amnion with processing procedures involving the use of Dispase II

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polysporin/Bacitracin/Mycostatin
Description: Application of Prepared antibiotic ointment: Polysporin, Bacitracin and Mycostatin combined
Study: NCT01384838

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: Nutritional, lifestyle and sports counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: counseling and controlled physical activity
Study: NCT00543309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide
Description: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: milrinone
Description: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo bolus on CPB, then placebo infusion
Study: NCT00741663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone and furosemide
Description: Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone and furosemide
Description: Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone and furosemide
Description: Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
Study: NCT01856309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg
Description: Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg
Description: Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
Study: NCT03370068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICSI
Description: Oocytes retrieved from one ovary will undergo insemination by ICSI.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional IVF
Description: Oocytes retrieved from the second ovary will undergo insemination by conventional IVF
Study: NCT00581646

Intervention type: BEHAVIORAL
Intervention: survey instrument
Description: Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.

Intervention type: BEHAVIORAL
Intervention: survey instrument
Description: Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.

Intervention type: BEHAVIORAL
Intervention: survey instrument
Description: Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.
Study: NCT01661452

Intervention type: OTHER
Intervention: Referral to counseling services if desired
Study: NCT04519437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987
Description: Administered subcutaneous (SC) every 4 weeks (Q4W)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneous (SC) every 4 weeks (Q4W)
Study: NCT02348385

Intervention type: DRUG
Intervention: Amphetamine
Description: Subjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.

Intervention type: DRUG
Intervention: Amphetamine
Description: Subjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
Study: NCT01578837

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginseng
Description: 2.25g of encapsulated ginseng (1.5g American Ginseng and 0.75g Rg3-enriched Korean Red Ginseng)will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Bran
Description: 2.25g of encapsulated 100% natural wheat bran will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
Study: NCT02800798

Intervention type: OTHER
Intervention: Preeclampsia positive

Intervention type: OTHER
Intervention: Preeclampsia positive
Study: NCT03164772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: anti-PD-L1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: anti-PD-L1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: anti-CTLA-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI 1361849
Description: mRNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI 1361849
Description: mRNA Vaccine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PharmaJet Tropis® device
Description: The PharmaJet Tropis® device was used for the intradermal administration of the BI 1361849 vaccine components.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PharmaJet Tropis® device
Description: The PharmaJet Tropis® device was used for the intradermal administration of the BI 1361849 vaccine components.
Study: NCT02920996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Merestinib is a potent and selective type II MET/RON kinase inhibitor with the ability to achieve inhibition of MET activity both in vitro and in vivo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Merestinib is a potent and selective type II MET/RON kinase inhibitor with the ability to achieve inhibition of MET activity both in vitro and in vivo.
Study: NCT00243932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coenzyme Q10
Description: antioxidant and mitochondrial cofactor, given in capsules three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coenzyme Q10
Description: antioxidant and mitochondrial cofactor, given in capsules three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, indistinguishable from CoQ10 capsules, given three times daily
Study: NCT02745522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01697696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long-acting beta 2-agonist (LABA)
Description: QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match QAB149
Study: NCT03608878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adagloxad simolenin/OBI-821
Description: Adagloxad simolenin (OBI-822) is a glyco-conjugated protein comprised of a carbohydrate tumor antigen. Globo H allyl glycoside is covalently linked to a carrier protein KLH, presented in a dominant trimer form with molecular weight between 1200-1395 kDa., to form Adagloxad simolenin (OBI-822) (Globo H-KLH) OBI-821 is a saponin based adjuvant structurally similar to descriptions found in the literature for another adjuvant, QS-21.~Adagloxad simolenin will be mixed with OBI-821 before administration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Transarterial chemoembolization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Transarterial chemoembolization
Study: NCT01350765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The LHWs of the selected intervention areas would receive additional training on ENC for identification, management and referral for birth asphyxia, lbw and neonatal sepsis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The LHWs in the control areas would perform their routine tasks as assigned to them by their program
Study: NCT04205201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drugs, Investigational
Description: To see the safety and efficacy of topical latanoprost compared with topical brimonidine in the treatment of the primary open angle

Intervention type: DRUG
Group type: OTHER
Intervention: Drugs, Investigational
Description: To see the safety and efficacy of topical latanoprost compared with topical brimonidine in the treatment of the primary open angle
Study: NCT00662753

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home monitoring
Description: Participants will receive a home blood pressure monitor and be taught how to use it. They will have an education session to review treatment goals, medications, diet and exercise. They will be asked to see their primary care provider at least every 3 months and the research nurse at 3, 6 and 12 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: monitor & phone call
Description: Participants will receive all of the same interventions of the home monitoring group plus they will receive scheduled telephone follow up by the research nurse
Study: NCT00679367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 10 mg/day D1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 5 mg/m2 D1-4
Study: NCT04251390

Intervention type: DEVICE
Intervention: trexo Home
Description: 12 week intervention, with weekly contact/assessments of the affects of using the trexo Home.
Study: NCT02041169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subsequent walking performance
Description: Subsequent walking performance